Neuronal forms of Gaucher disease
- PMID: 23563668
- DOI: 10.1007/978-3-7091-1511-4_20
Neuronal forms of Gaucher disease
Abstract
Gaucher disease is an inherited metabolic disease caused by the defective activity of the lysosomal enzyme, glucosylceramidase (GlcCerase), which is responsible for the last step in the degradation of complex glycosphingolipids. As a result, glucosylceramide (GlcCer) accumulates intracellularly. Little is known about the mechanisms by which GlcCer accumulation leads to Gaucher disease, particularly for the types of the disease in which severe neuropathology occurs. We now summarize recent advances in this area and in particular focus in the biochemical and cellular pathways that may cause neuronal defects. Most recent work has taken advantage of newly available mouse models, which mimic to a large extent human disease progression. Finally, we discuss observations of a genetic link between Gaucher disease and Parkinson's disease and discuss how this link has stimulated research into the basic biology of the previously underappreciated glycosphingolipid, GlcCer.
Similar articles
-
Phosphatidylcholine synthesis is elevated in neuronal models of Gaucher disease due to direct activation of CTP:phosphocholine cytidylyltransferase by glucosylceramide.FASEB J. 2002 Nov;16(13):1814-6. doi: 10.1096/fj.02-0149fje. Epub 2002 Sep 5. FASEB J. 2002. PMID: 12223447
-
Enhanced calcium release in the acute neuronopathic form of Gaucher disease.Neurobiol Dis. 2005 Feb;18(1):83-8. doi: 10.1016/j.nbd.2004.09.004. Neurobiol Dis. 2005. PMID: 15649698
-
Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration.Hum Mol Genet. 2014 Feb 15;23(4):843-54. doi: 10.1093/hmg/ddt468. Epub 2013 Sep 24. Hum Mol Genet. 2014. PMID: 24064337 Free PMC article.
-
Gaucher disease: pathological mechanisms and modern management.Br J Haematol. 2005 Apr;129(2):178-88. doi: 10.1111/j.1365-2141.2004.05351.x. Br J Haematol. 2005. PMID: 15813845 Review.
-
The metabolism of glucocerebrosides - From 1965 to the present.Mol Genet Metab. 2017 Jan-Feb;120(1-2):22-26. doi: 10.1016/j.ymgme.2016.11.390. Epub 2016 Dec 2. Mol Genet Metab. 2017. PMID: 27955980 Review.
Cited by
-
Mysterious sphingolipids: metabolic interrelationships at the center of pathophysiology.Front Physiol. 2024 Jan 3;14:1229108. doi: 10.3389/fphys.2023.1229108. eCollection 2023. Front Physiol. 2024. PMID: 38235387 Free PMC article. Review.
-
Antiviral activity of glucosylceramide synthase inhibitors in alphavirus infection of the central nervous system.Brain Commun. 2023 Mar 25;5(3):fcad086. doi: 10.1093/braincomms/fcad086. eCollection 2023. Brain Commun. 2023. PMID: 37168733 Free PMC article.
-
CRISPR/Cas9 Editing for Gaucher Disease Modelling.Int J Mol Sci. 2020 May 5;21(9):3268. doi: 10.3390/ijms21093268. Int J Mol Sci. 2020. PMID: 32380730 Free PMC article.
-
Neuroinflammatory paradigms in lysosomal storage diseases.Front Neurosci. 2015 Oct 30;9:417. doi: 10.3389/fnins.2015.00417. eCollection 2015. Front Neurosci. 2015. PMID: 26578874 Free PMC article. Review.
-
Deregulation of mTORC1-TFEB axis in human iPSC model of GBA1-associated Parkinson's disease.Front Neurosci. 2023 Jun 2;17:1152503. doi: 10.3389/fnins.2023.1152503. eCollection 2023. Front Neurosci. 2023. PMID: 37332877 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials